临床算法导向的方法,用于治疗帕金森病中轴立姿势异常的肉毒毒素A型治疗
Giacomo Argenziano1, Giovanna Squintani2, Serena Camozzi3
1Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS Reggio Emilia, Reggio Emilia, Italy.
Movement disorders clinical practice
|November 5, 2025
概括
毒素 (BTA) 注射在帕金森病 (PD) 中有效治疗轴立姿势异常 (APA),当由新的算法指导时. 这种方法可以改善干的姿势并减少疼痛,为PD患者提供更好的结果.
科学领域:
- 神经学 神经学
- 运动障碍 运动障碍
- 医疗技术 医疗技术 医学技术
背景情况:
- 轴姿势异常 (APAs) 是常见的,在帕金森病 (PD) 中造成残疾并发症.
- 在PD中APA的病理生理学尚未完全理解,这阻碍了有效的治疗.
- 肉毒素 (BTA) 显示出由于肌肉过活性的APAs的潜力,但需要标准化的应用.
研究的目的:
- 为了评估BTA注射对PD患者APAs的有效性.
- 为了利用一个临床算法,整合干角度严重性和电肌学 (EMG) 发现,以提供BTA指导.
- 评估BTA治疗后运动和非运动症状的改善情况.
主要方法:
- 进行了一项前性,开放标签的试点研究.
- 一个新的算法指导了BTA肌肉选择,基于干曲度和EMG数据.
- 患者接受了车角测量和轴肌EMG;结果在注射后一个月被评估.
主要成果:
- 在52名符合条件的PD患者中,20人接受了BTA治疗.
- 侧侧干屈曲 (LTF) 显著改善 (P=0.013),而前侧干屈曲 (ATF) 没有显著变化.
- 在临床整体姿势印象 (45%) 和疼痛 (50%) 中观察到改善,疼痛得分减少 (NRS P=0.010).
结论:
- 一个集成的临床和神经生理算法优化了PD中APA的BTA治疗.
- 这种方法可以改善干部错位,特别是LTF,以及相关的运动/非运动症状.
- 该算法促进了更有效的BTA应用,用于在帕金森病中禁用APA.
相关概念视频
Parkinson's Disease: Treatment
963
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
963
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.1K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.1K
Skeletal Muscle Relaxants: Therapeutic Uses
878
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
878
Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Depolarizing Blockers: Pharmocokinetics
559
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
559


